Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
about
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEphA2 is an essential mediator of UV radiation-induced apoptosisAnalysis of the genome to personalize therapy for melanomaThe mTOR signalling pathway in human cancerIn vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanomaEndoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatmentCurrent State of Animal (Mouse) Modeling in Melanoma ResearchMelanoma: new insights and new therapiesOptimal management of metastatic melanoma: current strategies and future directionsBeyond BRAF: where next for melanoma therapy?Emerging phytochemicals for prevention of melanoma invasionMelanoma: from mutations to medicineFrequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAFComputational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma CancerRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsA melanoma molecular disease modelSorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CAPhase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Melanoma genetics and the development of rational therapeutics.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.Understanding the biology of melanoma and therapeutic implicationsMechanisms of chromosomal instability in melanoma.Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.Melanoma: clinical features and genomic insights.Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasisLoss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions.Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsTargeted therapy for melanoma: a primer.Genotyping of cutaneous melanoma.Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.
P2860
Q54605986-9B4165DB-5354-47D9-B7D4-DD5B63581C51Q54896246-8290FA81-8BDB-4F40-A366-5A075DCCF416Q54896249-576873BD-A557-478D-B227-DBBF8DD8EC9AQ54896251-5AD796E0-C71E-49C9-83E2-DD0C7A6BAADCQ54899239-E8804495-EB1D-492A-931A-6DAA0AAC114DQ54899264-CD3AC567-F434-4EED-A55E-4D4259D777C5Q54899266-237B028F-767C-4B2F-AB6A-F2760595B78EQ54899283-FE19D07C-C36B-45FF-82FC-2FDCAE537897Q54903981-264999BC-232A-4824-A22D-8BA4667E8C18Q54905064-E037C3F4-B390-4E76-B25D-A673E335D95DQ54905141-88B73EFD-3A75-48A5-90FB-A1A43A7F4814Q54905452-7CA953F9-BE11-4939-84C7-D5828FB583BCQ54905455-EE70DD16-CE5F-4A02-A76A-D2E45FDB896FQ54905457-F4CDEF31-B61C-4381-831C-7E94AFFF4D39Q54905459-28ACCF5F-910E-412C-A4BF-419EC4BD9614Q54905504-E2CC2DF4-732A-480C-87E3-81106881D31DQ54905505-070FC74D-43D5-4542-8470-F1CCA941ECC2Q54905506-97274E76-E5A3-41AC-A66F-06022B543F5FQ54905838-722CF953-12BA-4E10-A6CA-220691B84384Q54906023-D09BF8A3-30B5-4C5E-9DBB-B98E39F29364Q54906134-EAE42E91-5745-40EB-B08B-3929ABC1630BQ54906183-067F96F5-809E-4FAF-A3F7-596088488B74Q54953784-8B26D47B-E6CF-42B0-87FE-BFDB38299809Q54953816-2CABC638-2A3F-44AA-A5DB-B8C4F7482C57Q54953937-E8FA9A17-E093-436E-B565-8B55D8BFE54CQ54954013-AA561C78-2AD9-4EA3-864E-6679D3714511Q54954059-D9B2ACCA-BC1A-42ED-A23F-809D7CF4168EQ54954130-D92D871F-C6DA-4569-A28E-7A586EABDFE9Q54954136-107445AF-D754-4D78-B491-83615AE8B5E2Q54954280-F42F8257-097E-4AE1-BE65-78655C53640EQ54970572-88564D15-06ED-4996-A821-50A561532ECDQ54973868-048BF149-82DA-4E19-8B50-DB6DB133273BQ54994157-1D020D69-8241-4867-9419-870192F50D59Q54994159-31BAF0E8-6784-4324-8DB8-DDD529A388EBQ54994187-AC0456D1-FE6E-4194-8069-98A42524777CQ54994197-917F0C9A-BB7D-472F-9D7C-BE006C7C6D07Q54994215-791BFDC8-C2D9-458A-A7F1-DA85FEDA9C86
P1343
Q21629049-8BE732C9-F359-4F53-9344-A7FF9BCFD91FQ24311103-911452A2-5AD4-4002-BFCD-FBA540C9D5EDQ24601008-A4D04427-EC82-4614-A4AF-90EEE04CE2A4Q24627306-7C2ED8DD-BFA0-46B7-B38C-69C2329493CEQ24629400-994753AA-6B1F-4FBC-BD0C-444296D415D6Q26776032-D907AA3F-F8B5-42C1-915D-D63776D75F03Q26781652-3ADBE4CD-0271-482B-B851-22010D870C72Q26853127-95836C8E-201D-4097-BE9E-82A56ABBF287Q26997338-779716B7-1373-4CA7-BDDA-00CF1E66C2A6Q27006853-6B17E7BC-BC0B-4E06-B42D-EB42326DB9D6Q27023283-315C639F-A488-497E-A4B2-84303E437EF7Q27024061-BE542CD9-DE13-48C8-8B33-02F6D63BE7B7Q27851617-F3F3DEBB-B716-4921-96F0-948D86963635Q27852401-B49DFA74-C4CF-4D37-848E-79CAC8B1CBF2Q28474973-957E48AC-7DAB-40CF-8C2D-F199D00AE5B8Q28551002-8714642F-7CE8-4B7C-A46A-520071EE4E7DQ28730438-45EC395C-FB27-43C9-9298-B1E7550A4344Q28741507-DF84C787-706A-4A38-9EDA-E97994B9A1ABQ30528973-3E0ACE7C-59E7-49EC-969F-518896ED9532Q33399049-8E78F335-BF64-44AF-BFAD-19AF8BA75857Q33439312-084B41F0-139F-49F3-B336-3E6F0D807B7AQ33560698-3A62262A-A811-4C23-B697-A4E68E3E3D63Q33725172-13318413-23A5-4B9E-860D-9322A58BA75FQ33726956-9610A4E6-708C-4D1E-BBEF-6E04EE0AAEC7Q33755862-8180A9D0-CFD2-43F0-988C-41B4F4480166Q33785885-4FAF6393-8A3E-4524-8D3B-DEBB42994892Q33978378-CA6A79E2-7186-418C-B629-84A4D6206909Q34026182-C511A904-4307-4546-BFC2-8609601375D8Q34041321-49A015DA-CD35-4059-B161-5F4643C30F4BQ34083191-56CB8530-EF69-419C-A498-DCF65283F5F6Q34144327-2216E9D8-E14D-445F-A035-EFE974120DE2Q34220097-936586CD-2E34-4C2D-999F-6B6B66DEAF53Q34244242-46703AF9-A3FE-458B-998D-9DC4575F3455Q34253185-F94A46C0-85FC-4185-A124-58D6B32F9A39Q34338564-B0B9BDBA-3000-4CE4-9B00-917D6740EE4EQ34382719-94E0640F-523F-41C1-9376-4C058BA3C1FEQ34438555-16D11A44-D4BB-4CF6-BDC2-FBDCB2C32C8AQ34540273-DF9CBFD9-15DA-44B6-B9D8-21F5C837CB7CQ34667738-4A528A4D-D355-4B96-9C81-9EF838ED0F8CQ34707834-4018C025-C579-4739-9D3F-CC21242CD104
P2860
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Genetic interaction between NR ...... MAC1 inactivation in melanoma.
@en
type
label
Genetic interaction between NR ...... MAC1 inactivation in melanoma.
@en
prefLabel
Genetic interaction between NR ...... MAC1 inactivation in melanoma.
@en
P2093
P2860
P4510
P1476
Genetic interaction between NR ...... MAC1 inactivation in melanoma.
@en
P2093
Frank G Haluska
Guang Yang
Hensin Tsao
Vikas Goel
P2860
P304
P356
10.1046/J.0022-202X.2004.22243.X
P407
P577
2004-02-01T00:00:00Z
P6179
1044089294